Graded A to F on human evidence · reviewed November 20, 2026
Best Peptide for Recovery (2026)
Peptides sold for recovery from injury, tendon or joint pain, graded on the human evidence for that goal. Neither one priced here has a randomized trial in people.
By Julian Caraulani · prices checked
For injury and tissue recovery, BPC-157 has the strongest human evidence of the peptides US programs sell: grade C (early human evidence). TB-500 grades D. None is FDA-approved for recovery when compounded. Grades follow our published rubric; prices come from each program's own page, with the date we read it.
Price checked Nov 19 · Medication included · No email needed
Recovery peptides, graded
Strongest evidence first. The grade covers injury and tissue recovery only; the same peptide can grade differently for another goal.
| Grade | Peptide | FDA status | Lowest price |
|---|---|---|---|
| C | BPC-157 Early human evidence Interim HHS enforcement discretion, acetate form, four routes. Not FDA-approved. | Interim HHS enforcement discretion, acetate form, four routes. Not FDA-approved. | $129/mo HealthRX, 3 programs |
| D | TB-500 Preclinical only Interim HHS enforcement discretion, acetate form, injection routes only. Not FDA-approved. | Interim HHS enforcement discretion, acetate form, injection routes only. Not FDA-approved. | $149/mo Superpower, 2 programs |
BPC-157 for recovery: grade C
Early human evidence
What the human evidence shows. Three small human studies, 30 people in all: a retrospective look at knee injections (16 people), a retrospective bladder study (12) and a two-person safety pilot. A 2026 systematic review rated the certainty of this evidence very low and found no randomized trial.
Sources: Poolton 2026, systematic review, Acta Orthop Belg. Read November 20, 2026.
Regulatory status: Interim HHS enforcement discretion, acetate form, four routes. Not FDA-approved.
“enforcement discretion for BPC-157 acetate is appropriate for subcutaneous, intramuscular, oral, and topical dosage forms” HHS Enforcement Discretion Policy with Appendices A and B, read November 18, 2026
BPC-157 programs, cheapest first
| Program | Plan | Price | Score | Visit |
|---|---|---|---|---|
BPC-157 injection, 12-month plan | BPC-157 injection, 12-month plan | $129/moread November 19, 2026 | 8.3/10 | Visit |
BPC-157 injection | BPC-157 injection | $144.50/moread November 20, 2026 | 8.3/10 | Visit |
BPC-157 injection (preorder) | BPC-157 injection (preorder) | $149/moread November 19, 2026 | 8.0/10 | Visit |
Every plan on cheapest BPC-157 · BPC-157 cost
TB-500 for recovery: grade D
Preclinical only
What the human evidence shows. We found no published human study of TB-500 itself. Its parent protein, thymosin beta-4, has been tested in people, but that is a different and larger molecule. FDA says it lacks safety information on TB-500 in people.
Sources: FDA: bulk drug substances that may present significant safety risks. Read November 20, 2026.
Regulatory status: Interim HHS enforcement discretion, acetate form, injection routes only. Not FDA-approved.
“enforcement discretion for TB-500 acetate appropriate for subcutaneous or intramuscular injectable dosage forms” HHS Enforcement Discretion Policy with Appendices A and B, read November 18, 2026
TB-500 programs, cheapest first
| Program | Plan | Price | Score | Visit |
|---|---|---|---|---|
TB-500 injection (preorder) | TB-500 injection (preorder) | $149/moread November 19, 2026 | 8.0/10 | Visit |
TB-500 injection | TB-500 injection | $159.50/moread November 20, 2026 | 8.3/10 | Visit |
Every plan on cheapest TB-500 · TB-500 cost
How these grades are set
One fixed rubric for every goal: A means FDA-approved for the goal, or at least two randomized trials in people that found a benefit. B means at least one human trial, or approval outside the US backed by trials. C means pilot or foreign-only human data. D means preclinical studies only. F means human trials found no benefit. When trials disagree, the grade drops one step. Read the full rubric.
We do not publish doses, schedules or combinations. A licensed prescriber decides whether any peptide suits you. Compounded peptides are not FDA-approved products.
Questions about peptides for recovery
What is the best peptide for recovery?
On human evidence, none earns better than a C for recovery. BPC-157 has three small uncontrolled human studies (grade C) and TB-500 has preclinical work only (grade D). Neither is FDA-approved. A prescriber decides whether either suits you.
Is BPC-157 better than TB-500 for recovery?
BPC-157 has a little human data and TB-500 has none we could find, so BPC-157 grades higher (C against D). Neither has a randomized trial in people. Our BPC-157 vs TB-500 guide compares them in more detail.
How do you grade peptides for recovery?
With one fixed A to F rubric for every goal: A means FDA-approved for the goal or at least two randomized trials in people that found a benefit; B at least one human trial or approval outside the US backed by trials; C pilot or foreign-only human data; D preclinical only; F human trials found no benefit. The full rules are on our methodology page.
Do you say how much to take?
No. We publish evidence grades, regulatory status and prices only. We do not publish doses, schedules or combinations. A licensed prescriber decides whether any of these suits you and how it is used.